Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 11pembrolizumab 10Gemcitabine 8Cisplatin 8Rituximab 7osimertinib 5durvalumab 5Specimen Handling 5Pemetrexed 5Nivolumab 5Dexamethasone 5belzutifan 4atezolizumab 4amivantamab 4Prednisone 4Paclitaxel 4Cyclophosphamide 4Bortezomib 4trastuzumab deruxtecan 3olaparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3alectinib 3acalabrutinib 3X-Rays 3Vinorelbine 3Oxaliplatin 3Midazolam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × olaparib × 90 days × Clear all
NCT03732820 2026-06-02

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

AstraZeneca

Phase 3 Active not recruiting
895 enrolled 19 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04269200 2026-06-01

DUO-E

AstraZeneca

Phase 3 Active not recruiting
805 enrolled 18 charts 1 FDA
Gynecologic

Endometrial Neoplasms

NCT02032823 2026-05-06

OlympiA

AstraZeneca

Phase 3 Active not recruiting
1,837 enrolled 20 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡